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Ouabain, an inhibitor of the Na+/K+-ATPase pump, was identiﬁed as an endogenous substance of human plasma. Ouabain has
been studied for its ability to interfere with various regulatory mechanisms. Despite the studies portraying the ability of ouabain
to modulate the immune response, little is known about the eﬀect of this substance on the inﬂammatory process. The aim of this
work was to study the eﬀects triggered by ouabain on inﬂammation and nociceptive models. Ouabain produced a reduction in
the mousepaw edema induced by carrageenan,compound48/80and zymosan.This anti-inﬂammatorypotential mightbe related
to the inhibition of prostaglandin E2, bradykinin, and mast-cell degranulation but not to histamine. Ouabain also modulated
the inﬂammation induced by concanavalin A by inhibiting cell migration. Besides that, ouabain presented antinociceptive
activity. Taken these data together, this work demonstrated, for the ﬁrst time, that ouabain presented in vivo analgesic and anti-
inﬂammatoryeﬀects.
1.Introduction
Ouabain, one of the oldest drugs used for treatment of car-
diac insuﬃciency, is classically known as a speciﬁc inhibitor
of the plasma membrane Na+/K+-ATPase [1]. Originally
isolated from plants, it was demonstrated that mammals
naturally produce an endogenous analogue of ouabain, a
hormone synthesized in the adrenal glands, hypothalamus,
and pituitary and found circulating in the plasma [2–5].
Accumulating evidence suggests that circulating levels of
endogenous ouabain are modulated by stress conditions.
Elevated plasma levels of ouabain were found in hyperten-
sive patients and after physical exercise in diﬀerent species
[6–8].
The steroid ouabain is capable of modulating many as-
pects of the immune system, being considered as an im-
munomodulatory molecule [9]. Ouabain, in vitro, inhibits
mitogen-induced thymocyte and lymphocyte proliferation
[10, 11], inhibits the generation of lymphokine-activated
killer (LAK) activity induced by IL-2 [12], increases intra-
cellular calcium levels [13], increases CD69 expression [14]
and acts both in vitro [15]a n din vivo [16] synergistically
with corticoids. In vitro, ouabain increases glucocorticoid-
induced plasma membrane depolarization in lymphoid cells
[9]. Besides that, ouabain downregulates mCD14 expression
on monocytes, which is related to inﬂammatory response
against severalpathogens[17]andinducesIL-1βproduction
on human mononuclear cells [18].2 Mediators of Inﬂammation
Additionally, this molecule is also capable of inducing
the activation of various signal transduction cascades that
are independent of changes in intracellular Na+ and K+ con-
centrations, involving the Ras/Raf/mitogen-activated protein
kinase(MAPK)cascade,transactivation ofepidermalgrowth
factor receptor (EGFR), and protein kinase C [17, 19–23]. In
murine thymocytes, ouabain decreased the levels of phos-
phorylated MAPK p38 and nuclear factor of activated T-cells
(NFATc1) induced by the mitogen concanavalin A [24].
Besides the eﬀects described in the immune system, little
is known about the role of ouabain in inﬂammatory pro-
cesses. During inﬂammation, a complex program of intra-
cellular signal transduction and transcription events, driven
by multiple proinﬂammatory mediators and cytokines, is
activated. The acute inﬂammation is characterized by exu-
dation of protein-rich ﬂuid, edema, vasodilatation, and cell
migration, primarily neutrophils, into the site of injury [25].
It was reported that ouabain suppressed the production of
the pro-inﬂammatory cytokines IL-6 and TNF-α stimulated
with LPS both in vitro and in vivo [26]. In addition, cardiac
glycoside drugs inhibits TNF-α/NF-κB signaling pathway,
which is a central common regulator for the process of in-
ﬂammation [27].
The aim ofthe present study was to investigate the role of
ouabain in acute peripheral inﬂammation induced by intra-
plantar and intraperitoneal injection of diﬀerent phlogistic
agents and in algesic processes.
2.MaterialandMethods
2.1. Animals. Female swiss albino mice (2 months old) were
housed in a temperature-controlledroom and receivedwater
and food ad libitum. After manipulation, euthanasia was
employed by cervical dislocation. The study was performed
according to the Guidelines on Ethical Standards for Investi-
gation of Experimental Pain in Animals [28], after approval
of protocol no. 0407/08 by the Institutional Ethics Commit-
tee of Laborat´ orio de Tecnologia Farmacˆ eutica.
2.2. Treatment with Ouabain. In all experiments, 0.56mg/kg
ouabain [16] or phosphate buﬀered saline (PBS) was given
intraperitoneally (i.p.) for three consecutive days. A dose-
response curve was also performed using 0.10mg/kg and
0.31mg/kg ouabain, and 0.56mg/kg ouabain was given i.p.
for one and two consecutive days.
2.3. Inﬂammatory Paw Edema. To induce inﬂammation,
mice received subcutaneous injections in the plantar surface
[29] of carrageenan (2.5%), compound 48/80 (2μg/paw),
zymosan (1%), histamine (100μg/paw), prostaglandin E2
(5μg/paw), and bradykinin (6 nmol/paw) in 20μLo fp h o s -
phate buﬀered saline (PBS) in the right (ipsilateral) hindpaw
and 20μL of PBS in the left (contralateral) hindpaw. Cap-
topril (5mg/kg) was used 1h prior to bradykinin challenge
in order to prevent the action of kininases [30]. Ouabain
last treatment was injected i.p. one hour before intraplantar
injections ofphlogisticagents. Allthe reagents were obtained
from Sigma. Hindpaw edema was measured with a digital
micrometer (Instrutemp 070393611) [31] and is expressed
as the diﬀerence of thickness (mm) between the stimulated
and the saline-injected paw.
Dexamethasone (0.5mg/kg), indomethacin (10mg/Kg)
and salbutamol (10mg/kg) were used as antiinﬂammatory
controls and injected i.p. or subcutaneous (s.c.) one hour
before intraplantar injections.
2.4. Peritoneal Inﬂammation Model. Mice were injected
intraperitoneally with60ugConcanavalin Adilutedin sterile
saline solutiontoa ﬁnal injection volumeof0.1mL onehour
after the last ouabain administration. After 24h, animals
were sacriﬁced and peritoneal lavage was performed with
10mL of sterile PBS [32–34] .T h eﬂ u i dw a sr e m o v e df o r
total and diﬀerential cell counts and results were reported
as cell number/mL of peritoneal wash. Diﬀerentiation of
leukocyte subpopulations in peritoneal lavage ﬂuids was
performed on cytospin preparations stained with Wright-
Giemsa solution (Sigma, St. Louis, Mo, USA). For each slide
a minimum of 100 cells was counted microscopically under
1000 magniﬁcation.
2.5. Acetic Acid Induced Writhing Test. Acetic acid admin-
istration causes irritation resulting in painful contortions
followed by extension of hind limbs [35]. The animals
were injected i.p. with 0.1mL/10g of 0.8% (v/v solution)
acetic acid one hour after the last treatment with ouabain
(0.56mg/kg). Morphine (6mg/Kg) (i.p.) was used for an-
algesia. Ten minutes after the administration of acetic acid,
mice were placed in separate boxes and the number of
abdominal writhes was counted for 10 minutes. The anti-
nociceptive activity was expressed as the reduction in the
number of abdominal writhes when compared to control
animals.
2.6. Hot Plate. Animals were placed on a hot plate main-
tained at 52 ± 1◦C. The time elapsed between placing the
animal on the hot plate, and the animal either licking its fore
or hind paws or jumping on the surface was considered the
response latency [36]. Mice with baseline latencies of more
than 15s were excluded from the study. Response latency
testing was measured 30, 60 and 120 minutes after the last
treatment with Ouabain (0.56mg/kg), saline or the positive
control, morphine (10mg/Kg). The cutoﬀ time for the hot-
plate test latency was set at 30s to avoid tissue injury. All
animals were brought to the test room at least 1h prior to
the experiments and were not tested more than once.
2.7. Possible Involvement of Opioid Receptors. In order to in-
vestigate the involvement of the opioidergic system in oua-
bain-induced antinociception, separate groups of mice were
pretreated with nonselective opioid receptor antagonist,
naloxone (5mg/kg, s.c.), which was injected 15min before
i.p. administration of ouabain (0.56mg/kg) and morphine
(10mg/kg, i.p.), and tested using the hot plate test [37].
2.8. Elevated Plus maze. The apparatus is comprised of two
open arms (35×5cm) and two closed arms (30×5×15cm)Mediators of Inﬂammation 3
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Figure 1: Ouabain dose-response curve and administrationfor 1 and 2 consecutive days. Mice were pretreated with 0.10mg/kg, 0.31mg/kg
and 0.56mg/kg ouabain for 3 consecutive days (a) or with 0.56mg/kg ouabain for 1 (b) and 2 consecutive days (c); one hour after the last
ouabaintreatment,micereceived intraplantarinjectionsofzymosanin20μLphosphatebuﬀered saline(PBS)inthe righthindpawand20μL
ofPBSinthelefthindpaw.Eachpointrepresents themeanofeightanimals.Dexametasone(DEXA,0.5mg/kg)wasusedasantiinﬂammatory
control and injected i.p. one hour before intraplantar challenge. Asterisks denote the signiﬁcance levels compared with ZYM group. Data
were expressed as mean ± S.E.M. and analyzed by software Graphpad Prism using Student’s t-test followed by unpaired test. ∗P<. 05,
∗∗P<. 01, and ∗∗∗P<. 001.
that extended from a common central platform (5 × 5cm).
T h ee n t i r em a z ew a se l e v a t e dt oah e i g h to f3 0 c ma b o v e
ﬂoorlevel[38].Onehourafter ouabainadministration, mice
were placed in the central region ofthe plus-maze apparatus.
Diazepan(0.5mg/Kg)wasadministred 30minbeforethetest
and used as positive control.
2.9. Statistical Analysis. All data were expressed as mean
± S.E.M. and analyzed by software Graphpad Prism using
Student’s t-test followed by unpaired test or ANOVA fol-
lowed Dunnett’s or Mann Whitney test , and the results were
considered signiﬁcant if P<. 05.
3.Results
3.1. Eﬀect of Ouabain on Carrageenan, Zymosan, and 48/80-
Induced Mice Paw Edema. The paw edema induced by
carrageenan and zymosan involves various mediators such
as histamine, bradykinin, and prostaglandins [39, 40].
Although 0.10mg/kg ouabainwas without eﬀect,0.31mg/kg
and 0.56mg/kg ouabain prevented zymosan edema forma-
tion (Figure 1(a)). On the other hand, ouabain was not
able to inhibit zymosan-induced paw inﬂammation when
administered only one day prior experiment (Figure 1(b)).
Furthermore, when ouabain was given for two days prior
experiment, it did not interfere in the edema present 4h4 Mediators of Inﬂammation
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Figure 2:Eﬀect ofthepretreatment with Ouabain(OUA, 0.56mg/kg)administeredintraperitoneally onpaw edema triggered by carragenan
(CAR),zymosan(ZYM),andcompound48/80inmice.Micereceived intraplantarinjectionsofcarrageenan(2.5%,(a)),zymosan(1%,(b)),
or compound 48/80 (2 μg/paw, (c)) in 20μL phosphate buﬀered saline (PBS) in the right hindpaw and 20μL of PBS in the left hindpaw.
Eachpointrepresents themeanofeightanimals.Indomethacin(IND, 10mg/Kg),dexametasone(DEXA,0.5mg/Kg),andsalbutamol(SALB,
10mg/kg) were used as antiinﬂammatorycontrols and injected i.p. one hour before intraplantar challenge. Asterisks denote the signiﬁcance
levels compared with CAR, ZYM, or compound 48/80 group. Data were expressed as mean ± S.E.M. and analyzed by software Graphpad
Prism using Student’s t-test followed by unpaired test ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001.
after zymosan (Figure1(c)).Ouabain 0.56mg/kginjected for
three consecutivedays, preventedzymosan edemaformation
at the 1st (54.4%), 2nd (47.1%), 3rd (34.7%), and 4th h
(26.9%) after treatment, as well as did 0.5mg/kg dexam-
ethasone (Figure 2(b)). Similarly to what was observed with
zymosan, carrageenan-induced paw edema was also signiﬁ-
cantlyreducedinatime-dependentmanner bythetreatment
of 0.56mg/Kg ouabain at 30min (54.9%), 1st (66.4%),
2nd (51.0%), and 5h (51.9%) after carrageenan treatment
(Figure 2(a)). On the other hand, ouabain did not interfere
in the edema present 24h after carrageenan injection. A
signiﬁcant antiinﬂammatory eﬀect of indomethacin at the
dose of 10mg/Kg was observed at all times studied. Paw
edema induced by compound 48/80 was short lasted, with a
peak 30min after injection. Ouabain signiﬁcantly inhibited
the edema, but to a lesser extent than salbutamol, at 30
(69.1%), 60 (79.7%), and 120min (49.7%) after compound
48/80 injection (Figure 2(c)).
3.2. Eﬀect of Ouabain on Paw Edema Triggered by Diﬀerent
Inﬂammatory Mediators. The results in Figure 3(a) indicate
that ouabain was incapable to inhibit the edema induced by
histamine at any of the times studied. On the other hand, the
administration of ouabain produced a signiﬁcant reduction
in the mouse paw edema induced by prostaglandin E2 and
bradykinin (Figures 3(b) and 3(c)). A signiﬁcant antiedemaMediators of Inﬂammation 5
∗∗
∗∗∗
∗∗∗
120 90 60 30 0
Time after injection (min)
0
0.25
0.5
0.75
1
1.25
P
a
w
e
d
e
m
a
(
m
m
)
HIS
OUA
DEXA
PBS
(a)
∗∗∗
∗∗∗
∗∗∗
60 45 30 15 0
Time after injection (min)
0
0.25
0.5
0.75
P
a
w
e
d
e
m
a
(
m
m
)
PGE2
OUA
DEXA
PBS
(b)
∗
∗∗
∗∗
30 15 0
Time after injection (min)
0
0.25
0.5
0.75
P
a
w
e
d
e
m
a
(
m
m
)
BRAD
OUA
DEXA
PBS
(c)
Figure 3: Eﬀect of the pretreatment with Ouabain (OUA, 0.56mg/kg) administered intraperitoneally on paw edema triggered by histamine
(HIS),prostaglandinE2(PGE2)andbradykinin (BRAD).Micereceived intraplantarinjectionsofhistamine(100μg/paw,(a)),prostaglandin
E2 (5μg/paw, (b)) or bradykinin (6nmol/paw, (c)) in 20μL of phosphate buﬀered saline (PBS) in the right hindpaw and 20μLo fP B Si n
the left hindpaw. Each point represents the mean of eight animals. Dexametasone (0.5mg/kg) was used as antiinﬂammatory control and
injected i.p. one hour before intraplantar challenge. Data were expressed as mean ± S . E . M .a n da n a l y z e db ys o f t w a r eG r a p h p a dP r i s mu s i n g
Student’s t-test followed by unpaired test ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001.
eﬀectofouabainwasobservedat15(79.8%),30(82.1%)and
60min (96.0%) after prostaglandin E2 challenge and at 15
(34.0%) but not at 30min after bradykinin challenge.
3.3. Eﬀect of Ouabain Treatment on theCellular Inﬂux into the
Peritoneal Cavity. Peritoneal inﬂammation was induced and
the number of cells recruited into the peritoneal cavity was
measured as an indication of the degree of inﬂammation.
As shown in Figure 4(a), the administration of ouabain
alone had no eﬀect on the number of resident peritoneal
cells in unchallenged mice. However, after induction of
inﬂammation, treatment with ouabain led to a 70%–80%
reduction in the total cell numbers in the peritoneal cavity
after 24h, as a reﬂex of the inhibition of polymorphonuclear
leukocytes (Figure 4(b)). These data are consistent with an
attenuated inﬂammatory response observed.
3.4. Eﬀect of Ouabain on Acetic Acid-Induced Writhing Re-
sponse. Theresultsofaceticacid-inducedwrithing responses
in mice, which indicate ouabain’s analgesic activity, were
presented in Figure 5(a). It was demonstrated that ouabain
caused a signiﬁcant inhibition (45%) on the writhing re-
sponses inducedbyaceticacidwhen compared tothecontrol
group, as well as did the analgesic drug, 6mg/kg morphine
(78%).
3.5. Eﬀect of Ouabain on the HotPlate Test and Involvement of
Opioid Receptors. The results of the hot plate test revealed6 Mediators of Inﬂammation
∗∗∗
OUA/Con A Con A OUA PBS
0
5
10
15
20
N
u
m
b
e
r
o
f
c
e
l
l
s
(
×
1
0
7
)
(a)
∗∗∗
OUA/Con A Con A OUA PBS
0
20
40
60
80
100
P
o
l
y
m
o
r
p
h
o
n
u
c
l
e
a
r
c
e
l
l
s
(
%
)
(b)
Figure 4: Eﬀect of the pretreatment with Ouabain (OUA, 0.56mg/kg) administered intraperitoneally on peritoneal inﬂammationtriggered
by ConcanavalinA(ConA, 60μg/300μL) ontotal(a)anddiﬀerential cell counts (b).Each bar represents the meanofnineanimals.Asterisks
denote the signiﬁcance levels compared with Con-A values. Data were expressed as mean ± S.E.M. and analyzed by software Graphpad
Prism using Student’s t-test followed by unpaired test ∗∗P<. 01 and ∗∗∗P<. 001.
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Figure 5: Eﬀect of the pretreatment with Ouabain (OUA, 0.56mg/kg) administered intraperitoneally on acetic acid-induced writhing and
hot plate test in mice. Each bar represents the mean of six or ten animals. Morphine (MOR, 10mg/kg) administered intraperitoneally was
used for analgesia. Naloxone (NLX, 5mg/kg), an opioid antagonist, was used to test the involvement of opioid receptors. Asterisks denote
the signiﬁcance level compared with control values; # compared with the Ouabain group and + compared with the morphine group. Data
were expressed as mean ± S.E.M. and analyzed by software Graphpad Prism using (ANOVA) followed Dunnett’s test. ∗P<. 05, ∗∗P<. 01,
and ∗∗∗P<. 001.
thatthelatencytimewasincreased (74%)whenanimals were
tested 30min after the last injection of ouabain. Pretreat-
ment of mice with naloxone inhibited the antinociceptive
eﬀect triggered by ouabain (around 77%). On the other
hand, ouabain was not capable to interfere in the latency
observed after 60 or 120min. The analgesic drug, morphine
(10mg/kg) modulated the pain, increased the latency time
(more than 70%), and it was signiﬁcantly reversed by
naloxone (70%), (Figure 5(b)).
3.6.Eﬀect of Ouabain on Elevated Plus-MazeTest. The results
of the elevated plus maze test revealed that ouabain did
not interfere in the numbers of entries in open arms but
increased the time spent (Figures 6(a) and 6(b)). Addition-
ally, the number of visits was not modiﬁed, and the time
spent in closed arms was decreased by ouabain (Figures 6(c)
and 6(d)). Ouabain did not interfere in total number
of entries (Figure 6(e)). The positive control (0.5mg/Kg
diazepan), increased the number total of entries as well the
number of entries and the time spent in open arms and
decreased the time spent in closed arms.
4.Discussion
In agreement with the immunosuppressive eﬀects that have
been previously observed, in the present work, ouabainMediators of Inﬂammation 7
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Figure 6: Eﬀect of the pretreatment with Ouabain (OUA 0.56mg/kg) administered intraperitoneally on elevated plus-maze test in mice.
(a)Number of visitto open-arms;(b) Timespent in open-arms;(c) Number ofvisitto closed-arms;(d) Timespent inclosed arms;(e) Total
numbers entries. Each bar represents the mean of seven or eight animals. Diazepan (DZP 0.5mg/Kg) was used as positive control. Data
were expressed as mean ± S.E.M. and analyzed by software Graphpad Prism using ANOVA followed Mann Whitney test or Student’s t-test
followed by unpaired test: ∗P<. 05, ∗∗P<. 01, and ∗∗∗P<. 001.
inhibited inﬂammation and nociception. To study the role of
ouabain in the inﬂammatory process, initially we used the
carrageenan and zymosan-induced paw edema. These mod-
els induce inﬂammatory responses, including edema forma-
tion, neutrophil inﬁltration, and the development of hyper-
algesia [41].
Ouabain administered for three consecutive days was
able to inhibit zymosan edema formation at all periods stud-
ied. On the other hand, ouabain was not able to inhibit zy-
mosan-induced paw inﬂammation when administered only
one day prior experiment. Furthermore, when ouabain was
given for two days prior experiment, it did not interfere in8 Mediators of Inﬂammation
the edema present 4h after zymosan. Despite the fact that
ouabain was eﬀective at the 0.31mg/kg concentration, the
dose of 0.56mg/kg was chosen because, using a diﬀerent
model, in a previous in vivo work, this concentration was
eﬀective [16]. The intraplantar administration of zymosan
activates of the complement system [42] promotes increased
expression of COX-2 and prostaglandin production, mainly
of type E2, and increases the production of nitric oxide [39].
A controversy exists regarding the role played by ouabain on
mast cell degranulation. Stimulatory and inhibitory eﬀects
were reported [43, 44]. Some data have also demonstrated
that ouabain had no eﬀect on mast cell degranulation [45].
In this work, the edema induced by mast cell degranulation
using compound 48/80 was also inhibited.
In agreement with the results using zymosan, ouabain
administered for three consecutive days was also able to
inhibit carrageenan induced edema formation. Henriques
and coworkers [46] showed that carrageenan injection into
the mouse paw induces a biphasic edema that develops
in the ﬁrst 6h, followed by a second phase, which starts
at 24h. The early phase is mainly mediated by histamine,
serotonin, and by an increasing synthesis of prostaglandins
suchasprostaglandinE2.Recentstudieshaveshownthatcar-
rageenan also inducesperipheral release of nitric oxide (NO)
sustained by TNF-α, IFN-y, and IL-1. These cytokines have
beenshown to induceiNOSina variety ofcells[47]. The late
phase is mainly sustained by prostaglandin release and NO
[48]. In the present work, we found that ouabain inhibits the
i n ﬂ a m m a t i o na f t e r3 0m i n ,1 ,2 ,a n d6hb u tn o ta f t e r2 4ho f
carrageenanchallenge.Theantiinﬂammatory eﬀectobserved
in the ﬁrst phases could be related to the suppression of the
pro-inﬂammatory cytokines IL-6 and TNF-α[26]a n db yt h e
blockade of the TNF-α/NF-κB signaling pathway [27].
Taking this information into account, the eﬀect of oua-
bain triggered by diﬀerent inﬂammatory mediators related
to carrageenan, zymosan, and compound 48/80-induced
mouse paw inﬂammation was carried out. The present re-
sults demonstrate that ouabain produced a signiﬁcant re-
duction in the mouse paw edema induced by prostaglandin
E2 and bradykinin (at 15 minutes) but did not interfere in
the edema induced by histamine. These ﬁndings suggest that
the antiinﬂammatory eﬀect of ouabain might be related to
theinhibition of prostaglandin E2,bradykinin, and mast-cell
degranulation but not to histamine.
Another feature of acute inﬂammation is cell migration,
primarily neutrophils, into the site of injury. The inhibitory
eﬀect of ouabain on neutrophil migration was conﬁrmed
through peritoneal inﬂammation induced by concanavalin-
A. This mitogen possesses chemotactic activity for neu-
trophils [49] and ouabain produced a clear inhibition in the
inﬂux of polymorphonuclear cells to the peritoneal cavity.
Together with the previous data, this result clearly demon-
strates that ouabain has an antiinﬂammatory eﬀect.
Prostaglandins are potent sensitizing agents able to mod-
ulate multiple sites of nociceptive pathways [50]. Prostaglan-
din E2 acts synergistically with bradykinin in the induction
of pain. These substances are among the most important
mediators of the inﬂammatory hyperalgesia [51–53]. Our
results demonstrated that ouabain produced a signiﬁcant
reductioninthemouse pawedemainducedbyprostaglandin
E2 and bradikynin. These data prompted us to evaluate the
role of Ouabain in the nociception.
Theaceticacid-inducedabdominalwrithing isasensitive
method to evaluate peripherally acting analgesics. In this
model, opioid mechanisms and released arachidonic acid
via cyclooxygenase and prostaglandin biosynthesis play a
role in the nociceptive mechanism [54–56]. In the present
work, it was demonstrated that ouabain and morphine,
caused a signiﬁcant inhibition, 45% and 78%, respectively,
on the writhing responses induced by acetic acid when
compared to the control group. This peripheral analgesic
potential might be related to the inhibition of PGE2 and
bradykinin, as we have also found that ouabain reduced the
edema formation induced by these mediators, suggesting
that ouabain antinociceptive eﬀect can be associated with an
antiinﬂammatory action.
To better evaluate the role of ouabain in pain, we used
the thermal model for nociception, the hot-plate test, which
is speciﬁc central antinociceptive test [57–59]. Ouabain was
found to have antinociceptive activity in the hot-plate test,
increasing the latency time (74%) when tested 30min but
not 60 nor 120min after the last injection of ouabain.
Animals were also pretreated with naloxone, an opioid
antagonist that opposes the eﬀects of opioid agonists such
as morphine [37]. The results demonstrated that naloxone
was capable to inhibit ouabain eﬀect, indicating that at least
in part, the antinociceptive eﬀect of ouabain is also related
to activation of opioid receptors. Using diﬀerent models, it
was also reported by other groups that ouabain exhibited
antinociceptive eﬀects [60, 61].
In an attempt to discard the possibility that the eﬀect
observed was due to a sedative eﬀect on the animal behavior
and not an analgesic eﬀect, further experiments were per-
formed, and mice were exposed to the elevated plus-maze
test [38, 62–64]. This test is based on the natural fear of open
and elevated spaces, and, as a consequence, rats and mice
tend to avoid the open arms and stay on the enclosed arms
[65, 66].It was reported that an increase in the proportion of
time spent in the open arms and in the proportion of entries
into the open arms indicates anxiety reduction [38]. On the
other hand, total number of arm entries is an indicator of
motor activity [62–64]. Ourdata demonstrated that ouabain
didnotinterfere inthemiceanxiety behaviororin themotor
function, when compared to the control group. As expected,
the positive control (0.5mg/Kg diazepan) leads to anxiety
reduction demonstrated by an increase in the number of
visits and time spent in the open arms and by an increase
in the total number entries. These results suggest that the
analgesic eﬀect of ouabain is not related to sedative eﬀect or
to motor function.
5.Conclusion
Fortheﬁrst time,thepresentwork demonstrated,invivo,the
antiinﬂammatory and analgesic potential of ouabain which
might be related to prostaglandin E2 and bradykinin as well
as to opioid mechanisms.Mediators of Inﬂammation 9
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